Though the results for full year 2012 were good, Q4'12 results showed a decline in net income from $424 million to $263 million. The management guidance for the full year is that the net product sales is expected to increase approximately 11 percent YoY to approximately $6.0 billion. The main product Revlimid which accounted for nearly 68% of its sales in 2012, is expected to contribute $4.1 billion in 2013 (compared with $3.767 billion in 2012), an increase of 10%. The GAAP diluted EPS is expected to be in the range of $4.67 to $4.79 ($3.30 per share for 2012), an expected increase of 41%. In fact, the guidance gave a fillip to the stock, and it has moved from around $80 in January to the $123 levels now. The company which is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases, acquired Avila Therapeutics in 2012. The acquisition was done to expand CELG's leadership role in hematologic cancers. CELG may also be on the lookout for acquisition of other companies in cancer research. Several companies are working on development of drugs for treatment of multiple myeloma like Senesco Technologies (SNTI). SNTI has a drug candidate SNS01-T which has a novel mechanism of action that has interested other researchers in the product. CELG has to continue its efforts to reduce dependency on Revlimid. Expiration of patents of such drugs brings in cheaper generic drugs which eats up the sales within months of expiry. The sudden declines have the potential to shake up companies of the size of CELG. In addition to this main drug, it has Abraxane, Vidaza and Thalomid which contributed $427 million, $823 million and $302 million respectively in 2012. Sales of Thalomid declined by 11% in 2012. The product pipeline for CELG revolves around a few drugs and it is imperative that it delivers new drugs and expands the use of existing drugs (in new indications) so that the growth story may continue.